Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the sale, the chief financial officer now owns 10,099 shares of the company’s stock, valued at approximately $5,060,204.94. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) traded up 1.19% during trading on Wednesday, reaching $500.22. 441,614 shares of the company’s stock traded hands. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55. The stock has a 50-day moving average of $485.79 and a 200-day moving average of $441.92. The company has a market capitalization of $53.04 billion, a price-to-earnings ratio of 50.18 and a beta of 1.65.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same quarter in the prior year, the business earned $2.82 earnings per share. The business’s quarterly revenue was up 21.2% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.85 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Robert E. Landry Sells 189 Shares of Regeneron Pharmaceuticals, Inc. (REGN) Stock” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://theolympiareport.com/2017/09/06/robert-e-landry-sells-189-shares-of-regeneron-pharmaceuticals-inc-regn-stock.html.

Institutional investors have recently added to or reduced their stakes in the company. National Pension Service increased its position in shares of Regeneron Pharmaceuticals by 10.8% in the second quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock worth $33,920,000 after acquiring an additional 6,481 shares in the last quarter. Princeton Capital Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 6.7% in the first quarter. Princeton Capital Management Inc. now owns 2,496 shares of the biopharmaceutical company’s stock worth $967,000 after acquiring an additional 157 shares in the last quarter. CIBC World Markets Inc. increased its position in shares of Regeneron Pharmaceuticals by 2,190.6% in the first quarter. CIBC World Markets Inc. now owns 21,784 shares of the biopharmaceutical company’s stock worth $8,442,000 after acquiring an additional 20,833 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 2.4% in the second quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock worth $56,580,000 after acquiring an additional 2,646 shares in the last quarter. Finally, Oppenheimer & Co. Inc. increased its position in shares of Regeneron Pharmaceuticals by 3.4% in the first quarter. Oppenheimer & Co. Inc. now owns 5,808 shares of the biopharmaceutical company’s stock worth $2,251,000 after acquiring an additional 189 shares in the last quarter. 67.96% of the stock is owned by institutional investors.

REGN has been the subject of a number of recent analyst reports. Leerink Swann restated a “positive” rating and set a $552.00 price target (down previously from $580.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Sanford C. Bernstein restated an “outperform” rating on shares of Regeneron Pharmaceuticals in a report on Thursday, May 25th. Piper Jaffray Companies restated an “overweight” rating and set a $557.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 1st. Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 16th. They set an “outperform” rating and a $605.00 price target for the company. Finally, Barclays PLC restated an “equal weight” rating and set a $450.00 price target (up previously from $400.00) on shares of Regeneron Pharmaceuticals in a report on Saturday, July 22nd. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Hold” and an average price target of $496.35.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.